Wang, Q. T., Y. Nie, S. N. Sun, T. Lin, R. J. Han, J. Jiang, Z. Li, J. Q. Li, Y. P. Xiao, Y. Y. Fan, X. H. Yuan, H. Zhang, B. B. Zhao, M. Zeng, S. Y. Li, H. X. Liao, J. Zhang and Y. W. He (2020). "Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients." Cancer Immunol Immunother 69(7): 1375-1387.

Patients with glioblastoma multiforme (GBM) or advanced lung cancer received DC vaccines transfected with personalized TAA panels, in combination with low-dose cyclophosphamide, poly I:C, imiquimod and anti-PD-1 antibody. Among the seven patients tested for anti-TAA T cell responses, most of the TAAs induced antigen-specific CD4+ and/or CD8+ T cell responses, regardless of their expression levels in the tumor tissues. These results support further studies on DC immunization with personalized TAA panels for combined immunotherapeutic regimens in solid tumor patients.